PolyActiva Secures $40M in Series C Financing to Advance PREZIA™ Platform Technology and Drive Innovation in Sustained Ocular Drug Delivery
active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom